BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/10/2023 1:26:04 PM | Browse: 161 | Download: 537
 |
Received |
|
2023-05-10 07:42 |
|
Peer-Review Started |
|
2023-05-10 07:44 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-07-09 03:05 |
|
Revised |
|
2023-07-18 07:17 |
|
Second Decision |
|
2023-07-28 02:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-07-28 07:41 |
|
Articles in Press |
|
2023-07-28 07:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-08-03 06:19 |
|
Publish the Manuscript Online |
|
2023-08-10 13:26 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Systemic treatments for resectable carcinoma of the esophagus
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana, Pathomthep Leowattana and Tawithep Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, BMed, MD, MSc, PhD, Professor, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi road, Rachatawee 10400, Bangkok, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
Systemic treatment; Resectable carcinoma of the esophagus; Personalized medicine; Biomarkers; Chemotherapy; Chemoradiotherapy; Immunotherapy; Immune checkpoint inhibitors |
| Core Tip |
Despite improvements in neoadjuvant and adjuvant treatment approaches in recent years, the average life expectancy of patients with resectable esophageal cancer (EC) still falls below 5 years. Immunotherapy has been effectively used as a first-line therapy for many oncological diseases at advanced stages for over ten years. Immunotherapy drugs are also making great progress in resectable situations, while it is still debatable whether this treatment should be limited to a certain patient subgroup based on biomarker selection. In order to treat resectable EC, immunotherapy, in particular immune checkpoint inhibitors, has made significant strides. This review also provides a brief overview of potential ongoing clinical studies. |
| Publish Date |
2023-08-10 13:26 |
| Citation |
Leowattana W, Leowattana P, Leowattana T. Systemic treatments for resectable carcinoma of the esophagus. World J Gastroenterol 2023; 29(30): 4628-4641 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i30/4628.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i30.4628 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
